Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Reported annual fiscal-period values; no daily interpolation.
PEG RATIO
N/A
PEG RATIO AVG TTM
5.21
PEG RATIO AVG 3Y
5.21
PEG RATIO AVG 5Y
4.55
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$32.38B
PEG Ratio
4.14
TTM Avg
2.27
3Y Avg
2.27
5Y Avg
1.52
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alcon Inc. (ALC) | $34.88B | N/A | 5.21 | 5.21 | 4.55 |
| ResMed Inc. (RMD)vs › | $34.60B | 2.00 | 1.36 | 1.79 | 1.56 |
| DexCom, Inc. (DXCM)vs › | $34.13B | 0.67 | 19.51 | 10.66 | 8.56 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.38B | 4.14 | 2.27 | 2.27 | 1.52 |
| Zoetis Inc. (ZTS)vs › | $32.15B | 2.04 | 2.96 | 3.83 | 3.78 |
| Biogen Inc. (BIIB)vs › | $32.10B | N/A | 0.34 | 0.24 | 0.23 |
| Centene Corp. (CNC)vs › | $31.95B | N/A | 0.18 | 0.16 | 0.16 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.37B | N/A | 1.85 | 3.49 | 3.16 |
| Waters Corporation (WAT)vs › | $31.00B | 75.61 | 75.61 | 40.77 | 27.51 |
| Medline Inc. (MDLN)vs › | $29.72B | N/A | 0.07 | 0.07 | 0.07 |
PEG Ratio
N/A
P/E Ratio
55.6
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 10.20 |
| 2023-12-31 | 0.21 |
| 2020-12-31 | 3.24 |
| 2018-12-31 | 0.67 |
| 2016-12-31 | 1.05 |
